Page 4 - உலர்ந்த கண் நோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from உலர்ந்த கண் நோய். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In உலர்ந்த கண் நோய் Today - Breaking & Trending Today

Oculis Selects AGC Biologics' Heidelberg Facility to Manufacture OCS-02

Oculis Selects AGC Biologics Heidelberg Facility to Manufacture OCS-02
Seattle, May 06, 2021 (GLOBE NEWSWIRE) AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with Oculis to manufacture OCS-02, a Phase II investigational drug targeting both Dry Eye Disease and Anterior Uveitis, at its Heidelberg facility.
We are very pleased that Oculis has chosen us to manufacture this treatment, says AGC Biologics Chief Business Officer, Mark Womack. Our Heidelberg site has the experience and expertise to deliver this program from early phase to market.
OCS-02 is a tumor necrosis factor-alpha (TNF alpha) inhibitor. TNF alpha is a proven biological target in ocular inflammation with possible dual actions: anti-inflammation and anti-necrosis. The OCS-02 compound is based on a proprietary single-chain antibody fragment technology specifically designed for topical delivery. The efficacy and ....

United States , Baden Wüberg , Dieter Kramer , Mark Womack , Contract Development , Biopharmaceutical Contract Development , Manufacturing Organization , Dry Eye Disease , Anterior Uveitis , Chief Business Officer , Non Infectious Anterior , General Manager , Gene Therapy , ஒன்றுபட்டது மாநிலங்களில் , குறி வோமேக் , ஒப்பந்த வளர்ச்சி , உற்பத்தி ஆர்கநைஸேஶந் , உலர்ந்த கண் நோய் , தலைமை வணிக அதிகாரி , ஜநரல் மேலாளர் , கீந் சிகிச்சை ,

Outlook on the Dry Eye Disease (DED) Global Market to 2026

4. Global Dry Eye Disease Market: Sizing and Forecast
5. Global Dry Eye Disease Market Segmentation By Disease, By Treatment, By End User, By Distribution Channel
5.1 Competitive Scenario of Global Dry Eye Disease Market: By Disease
5.1.1 Aqueous n Market Size and Forecast (2016-2026)
5.1.2 Evaporative n Market Size and Forecast (2016-2026)
5.1.3 Others n Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Dry Eye Disease Market: By Treatment
5.2.1 Eye Drops n Market Size and Forecast (2016-2026)
5.2.2 Anti-Inflammatory Drugs n Market Size and Forecast (2016-2026)
5.2.3 Others n Market Size and Forecast (2016-2026)
5.3 Competitive Scenario of Global Dry Eye Disease Market: By End User
5.3.1 Home Healthcare n Market Size and Forecast (2016-2026) ....

United States , Hong Kong , United Kingdom , South Korea , Novaliq Gmb , Asia Pacific , Company Profiles Business Description , Research Methodology , Sentiss Pharma Pvt Ltd , Santen Pharmaceuticals Co , Bausch Health , Dry Eye Disease , End User , Distribution Channel , Market Insights , Evaporative Dry Eye Disease , North America , Dry Eye Disease Market By , Eye Drops , Anti Inflammatory Drugs , Home Healthcare , Hospital Pharmacies , Global Dry Eye Disease Market , Major Mergers , Technological Innovations , Santen Pharmaceuticals ,

Oculis Announces an Oversubscribed US$57 million Series C Financing

Oculis Announces an Oversubscribed US$57 million Series C Financing
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong Kong , David Weber , Citigate Dewe Rogersonmark , Louie Anne Gauthier , Vanessa Huang , Thorsteinn Loftsson , Multi Family Office , Vi Partners Swiss Innovation Fund , Nan Fung Life Sciences , Novartis Venture Fund , Management Ltd , Hyfinity Investments , Bay City Capital , Brunnur Ventures , Tekla Capital Management , Venture Partners , Diabetic Macular Edema , Dry Eye Disease , Chronic Anterior Uveitis , Acute Anterior , General Partner , Managing Partner , Oculis Board , Riad Sherif , Venture Incubator , Life Science ,

Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in Vision and Ophthalmology 2021 Virtual Annual Meeting

Home / Top News / Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in Vision and Ophthalmology 2021 Virtual Annual Meeting
Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in Vision and Ophthalmology 2021 Virtual Annual Meeting
PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, announced today the presentation of data analyses from its Phase 3 ONSET-2 clinical trial evaluating OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Annual Meeting, being held on May 1-5. ....

United States , Michael Raizman , Sheryl Seapy , Tim Mccarthy , Oyster Point Pharma Inc , Exchange Commission , O Group , Association For Research , Oyster Point Pharma , Annual Meeting , Virtual Podium , Dry Eye Disease , Dry Eye Clinical Treatments , Point Pharma , Private Securities Litigation Reform Act , ஒன்றுபட்டது மாநிலங்களில் , மைக்கேல் றைஜ்மன் , நேரம் ம்க்கார்தீ , ஆய்ஸ்டர் பாயஂட் பார்மா இன்க் , பரிமாற்றம் தரகு , ஓ குழு , சங்கம் க்கு ஆராய்ச்சி , ஆய்ஸ்டர் பாயஂட் பார்மா , ஆண்டு சந்தித்தல் , மெய்நிகர் போடியம் , உலர்ந்த கண் நோய் ,

Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for .
Oyster Point Pharma, Inc.May 1, 2021 GMT
PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, announced today the presentation of data analyses from its Phase 3 ONSET-2 clinical trial evaluating OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Annual Meeting, being held on May 1-5. ....

United States , Michael Raizman , Sheryl Seapy , Tim Mccarthy , Oyster Point Pharma Inc , Exchange Commission , O Group , Association For Research , Point Pharma , Annual Meeting , Virtual Podium , Dry Eye Disease , Dry Eye Clinical Treatments , Nasal Spray , Oyster Point Pharma , Private Securities Litigation Reform Act , Globe Newswire , Corona Virus , ஒன்றுபட்டது மாநிலங்களில் , மைக்கேல் றைஜ்மன் , நேரம் ம்க்கார்தீ , ஆய்ஸ்டர் பாயஂட் பார்மா இன்க் , பரிமாற்றம் தரகு , ஓ குழு , சங்கம் க்கு ஆராய்ச்சி , பாயஂட் பார்மா ,